Save Product
Product Details
FAB
- Comprehensive validation - Validated with various antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
Product Specifications
Assay TypeCompetition-TR-FRETReactivityHumanRegulatory StatusRUOAssay Time1 hrSample volume10 μLProduct Overview
The Human APRIL / BCMA Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screen for inhibitors of human APRIL binding to BCMA within one hour. It can also be used as a universal detection tool to identify the ability of human APRIL to bind to human BCMA.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Materials Provided
IDComponentsSizeFRTP025-C01Human APRIL Protein Europium-chelate100 tests/500 testsFRTP025-C02FA Labeled Human BCMA Protein100 tests/500 testsFRTP025-C03Anti-Human APRIL Antibody30 μg/100 tests 150 μg/500 testsDB-04TR-FRET Sample Dilution Buffer, pH7.450 mL/100 tests & 500 testsDB-05TR-FRET Detection Buffer, pH7.450 mL/100 tests & 500 testsAssay Principles
This Human APRIL / BCMA Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human APRIL and Europium-chelate labeled streptavidin as the Donor and FA Labeled Human BCMA Protein as the Acceptor.
— When the sample does not contain the inhibitors that block the binding of human APRIL to human BCMA, the Donor and Acceptor are in close proximity because of the binding of human APRIL and human BCMA. Upon Donor excitation with light of a specific wavelength (337 nm), in addition to Donor emission (620 nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665 nm).
— When the sample contains the inhibitors that block the binding of human APRIL to human BCMA, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-TR-FRET
Please refer to DS document for the assay protocol.
In this TR-FRET assay, Human APRIL Protein Europium-chelate is used as the Donor and FA Labeled Human BCMA Protein is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between human APRIL and human BCMA using Anti-Human APRIL Antibody resulting in a typical IC50 of 0.8564 nM (QC tested).
The kit is suitable for the detection and characterization of human APRIL / BCMA inhibitors. It was shown that the Anti-APRIL (Sibeprenlimab) disrupted the interaction, with an IC50 of 0.6343 nM. The Anti-TNF-alpha (Adalimumab) antibody showed no significant inhibitory effect in the assay as expected.
Customer Reviews Writing Reviews
Recent Advances
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Drug Candidate Licensing
